The HonorHealth Research Institute in Scottsdale is offering a first-of-its-kind clinical trial for children and teens with Type 2 diabetes.
The trial will test once-a-week injections on children from 10 to 17 years old. Usually, adolescents with the disease control their blood-sugar levels with daily insulin injections.
Dr. James Swain is the medical director of the Research Institute’s GI/Bariatrics Research Division. He said a new medication (LY3209590) allows the insulin to be released over time, so kids would have to get fewer shots.
“Any time a patient has to take an injection, that’s not the funnest thing in the world for adolescents," Swain said. "So in order to better control their diabetes, we can also limit their times that they actually have to poke themselves which will decrease pain, bruising, insertion site infections - all those different things.”
The shot has already proven to be safe and effective for adults with Type 2 diabetes. To qualify for the trial, participants must have HbA1c levels (a long-term indicator of blood sugar levels) of between 6.5% and 9.5%, and not have taken insulin within the past three months.
"So a lot of these patients would be not necessarily perfectly well-controlled and that's the exact people we want," Swain said.
Families who decide to participate in the trial will be compensated for their time. For more information, call 480-323-1292.
EDITOR'S NOTE: Due to a HonorHealth error, this story has been updated to correct the trial's phone number.
-
Phoenix has distributed more than 10,000 kits during the first year of its naloxone program. -
Many young people, including those from marginalized groups, say their mental well-being is tied to feeling safe and supported in their environments, according to the latest Youth Risk Behavior Survey from the CDC. -
Arizonans who get their health coverage through the state’s Medicaid program can now be reimbursed for the costs of doula care. -
A national nonprofit that empowers individuals to talk about menopause has launched a campaign to remove what it calls “outdated and misleading” FDA warnings on vaginal estrogen, which is used to treat a very common condition in postmenopausal women. -
The good news? There’s much more awareness about menopause, specifically hormone therapy. The bad news? There’s a lot of misinformation being pushed out by some medical providers.
